Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Multimorbidity and treatment burden
Medicine of older adults · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Do not let complexity hide deterioration
Hypoxia, sepsis, acute coronary syndrome, stroke, hypoglycaemia, bleeding, acute kidney injury and medicine toxicity can appear as falls, confusion or loss of function in multimorbidity.
Action: Stabilise and investigate the acute syndrome, reconcile medicines and recent changes immediately, then revise chronic targets only after physiology, baseline, prognosis and the person's goals are clear.
Purpose and principles
Integrate multiple long-term conditions around the person's priorities, identify interacting disease and medicine harm, reduce unmanageable treatment workload, and coordinate proportionate evidence-based care without abandoning beneficial treatment.
Begin with the person's priorities: symptom relief, mobility, cognition, independence, longevity, time at home or fewer appointments. Ask which treatment is hardest and which outcome is unacceptable. Map diseases, prognosis, functional reserve and social support, but avoid assuming that frailty means prevention has no value.
Reconcile all prescribed, non-prescription and intermittent products from reliable sources. Look for duplicate therapeutic classes, prescribing cascades, anticholinergic and sedative load, renal dosing, hypotension, hypoglycaemia, bleeding, constipation and adherence barriers. Identify who initiated each medicine and who receives monitoring results.
Estimate likely benefit and time to benefit for each intervention against competing risks and current priorities. Blood-pressure, glycaemic and lipid targets may need individualisation, but do not relax them automatically by age. A short-horizon symptomatic medicine can be valuable even in limited prognosis, while a burdensome preventive intervention may offer little chance of desired benefit.
Indications, selection and cautions
Guideline collision
Recommended treatment for one disease worsens another condition or undermines a higher personal priority.
Medicine-related syndromeRed flag
Falls, confusion, anorexia, retention or postural symptoms emerge after cumulative or recently changed treatment.
Workload-capacity imbalance
The regimen demands more time, cognition, dexterity, transport or carer input than the household can sustain.
Prescribing cascade
An adverse drug effect is interpreted as a new condition and treated with another medicine.
Fragmented ownership
Several clinicians order overlapping monitoring or assume another service will act on results.
Hidden non-adherence
Missed doses reflect burden, beliefs, swallowing, sensory or cognitive barriers rather than wilful refusal.
Red flags requiring action
A new symptom attributed to one known disease may represent a second emergency; avoid diagnostic overshadowing.
Recent discharge, several prescribers, renal decline or duplicate brands creates high risk of omission, interaction and dosing error.
Dizziness, falls, anorexia, confusion, constipation or incontinence may be cumulative medicine harm rather than another diagnosis.
Assessment before treatment
01Priority and burden interviewFirst step
Why
Identify desired outcomes and the treatment work that threatens them.
Interpretation and limitations
Ask what matters, what is hardest, which harms occur and what the person would change first.
02Two-source medicine reconciliation
Why
Establish what is actually taken.
Interpretation and limitations
Compare record, pharmacy, packets and person or carer account including OTC products and recent changes.
03Indication-benefit-harm review
Why
Judge net value medicine by medicine.
Interpretation and limitations
Record indication, benefit horizon, current control, adverse effects, interactions, organ function and monitoring.
04Functional administration assessment
Why
Test whether the regimen is feasible.
Interpretation and limitations
Assess vision, hearing, dexterity, cognition, swallowing, packaging, timing, transport and carer capacity.
05Targeted safety tests
Why
Find treatment toxicity and disease interaction.
Interpretation and limitations
Select renal, liver, electrolytes, FBC, glucose, lying-standing pressure, ECG or drug-specific monitoring from the regimen.
Treatment approach
01First-line reviewPrioritise, reconcile and identify harmFirst stepFirst lineSeveral conditions or medicines create difficult decisions.+
1Treat urgent deterioration and ask which outcomes and burdens matter most to the person.
2Reconcile treatment and assess interactions, benefit horizon, adverse effects, feasibility and monitoring ownership.
3Agree a small prioritised set of optimisations with explicit review and contingency criteria.
02Deprescribing sequenceWithdraw safely and learn from responseA medicine has low expected benefit, current harm or unacceptable workload.+
1Confirm indication, history, alternatives and whether tapering or specialist discussion is required.
2Share the trade-off, change cautiously and document symptoms, observations or tests that will measure effect.
Complications, monitoring and follow-up
Review symptoms, function and personally important outcomes as well as disease biomarkers after each change.
Check renal function, electrolytes, blood pressure, glucose, bleeding and cognition according to the medicines retained.
Ask whether the simplified plan is actually easier for the person and carer and whether adherence improved.
Track withdrawal and recurrence explicitly so stopped medicines are not restarted automatically at transitions.
Reconcile at every admission and discharge and ensure one clinician owns outstanding tests and target review.
Special situations
More diagnoses do not equal more care
Complexity arises from interactions, burden and goals, not the problem-list length alone.
Non-adherence is information
It often identifies an infeasible regimen, adverse effects or priorities that have never been discussed.
Deprescribing is active treatment
A safe withdrawal has a rationale, method, outcome measure and contingency plan.
Benefit has a time horizon
Preventive value depends on the chance of living long enough to experience it and the burden paid now.
Coordination is an intervention
A single accountable plan can reduce harm even without changing the number of medicines.
Common pitfalls
01
Applying every single-disease target without considering collisions and workload.
02
Stopping all preventive treatment solely because a person is old or frail.
03
Calling missed doses non-compliance without assessing capacity, packaging, adverse effects and beliefs.
04
Using a dosette box for a complex changing regimen without testing whether it solves the problem.
05
Abruptly stopping a withdrawal-prone medicine without a taper and contingency plan.
06
Leaving monitoring results unowned between specialists and primary care.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Medicine of older adultsOriginal SBA
Identifying treatment burden
A woman attends nine clinics, takes medicines at six daily times and misses doses while caring for her husband. Which response best follows multimorbidity guidance?
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Find guideline collisions: NSAID with CKD and anticoagulation, intensive diabetes treatment with recurrent falls, diuretic and ACE inhibition during dehydration, or anticholinergic treatment worsening cognition and retention. Discuss uncertainty with relevant specialists and the person rather than applying each disease pathway independently.
Reduce workload by once-daily dosing where clinically equivalent, synchronised refills and blood tests, accessible packaging, home monitoring only when useful and combined appointments. Assess swallowing, vision, dexterity and cognition. Dosette boxes do not solve deliberate non-use, fluctuating doses or inability to recognise adverse effects.
For deprescribing, agree the target symptom or risk, select the lowest-value or highest-harm medicine, check withdrawal needs and change one or a small number at a time. Taper corticosteroids, benzodiazepines, some antidepressants, beta-blockers and opioids when abrupt cessation is unsafe. Record review date and what would prompt restart.
Create one care plan listing active priorities, accepted trade-offs, emergency contingencies and responsible clinicians. Reassess symptoms, function, disease control, adverse effects and burden after changes. If an apparently simpler regimen worsens breathlessness, pain or mood, revisit rather than defending the deprescribing decision.
Include non-medicine treatment in the burden calculation. Oxygen equipment, compression, catheters, glucose sensors, exercise prescriptions and dietary restrictions can conflict with each other or dominate a household. Ask which instructions are followed on a difficult day and whether one plan undermines another. When evidence is weak, prioritise treatments that improve a named outcome soon, avoid duplicative monitoring and state explicitly which lower-priority target is being relaxed and why.
Transitions are a predictable hazard. Hospital formularies, temporary sick-day changes and specialist recommendations can create conflicting lists. At discharge identify which drugs are permanently stopped, temporarily held or newly time-limited, why each changed, who checks renal function or observations and when a held drug should restart. Send the same reconciled list to the person, community pharmacy, primary care and relevant specialists and remove obsolete repeats.
Key points
Multimorbidity means several conditions whose combined management materially affects daily life; counting diagnoses alone does not measure complexity.
Treatment burden includes dosing, monitoring, appointments, travel, self-management, adverse effects, equipment and work transferred to carers.
First-line review asks what matters most, identifies urgent problems and medicines, estimates benefit horizon and creates one prioritised plan.
Use NICE single-disease guidance as evidence, then adapt recommendations when interactions, frailty, prognosis or burden change net benefit.
Medication review links every drug to indication, benefit, current harm, renal or hepatic suitability, adherence and monitoring owner.
Deprescribing is planned withdrawal with shared rationale, taper where required, monitoring and restart criteria; it is not indiscriminate undertreatment.
Optimise high-value treatments and simplify timing, formulations, monitoring and appointments before concluding that the person refuses care.
Agree one coordinating clinician and a single problem list so specialists do not create contradictory targets or duplicate tests.
Capacity is decision-specific; support communication and involve an attorney or best-interests process only when needed.
Recurrent hypoglycaemia, postural hypotension or anticoagulant bleeding indicates targets or regimens may be causing immediate net harm.
Non-adherence may reflect impossible workload, dexterity, cognition, cost or beliefs and requires exploration rather than blame.
Carers administering complex treatment without training or respite may be at risk of error and burnout.
06Coordination map
Why
Expose treatment duplication and ownership gaps.
Interpretation and limitations
List prescribers, appointments, tests, result owners, contingency contacts and conflicting disease targets.
3
Review at the agreed interval and restart, modify or continue withdrawal according to the person's outcome.
03Integrated planningResolve guideline conflict and workloadSeveral disease-specific plans cannot all be delivered safely.+
1Bring relevant clinicians, pharmacy, the person and carer around one problem and priority list.
2Choose targets and treatments by likely net benefit, feasibility and values rather than diagnosis count.
3Name one coordinator, align reviews and communicate accepted trade-offs across services.
Review after any change because stopping one medicine can unmask symptoms or alter another condition.